GlycoMimetics to Present at Biocentury’s Newsmakers in the Biotech Industry Conference

GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief Executive Officer Rachel King will present at BioCentury’s Newsmakers in the Biotech Industry Conference. The presentation will take place on Friday, September 8, 2017 at 1:30 p.m. ET in room 311 of the Millennium Broadway Hotel in New York City.

To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at www.glycomimetics.com.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial for the treatment of multiple myeloma. The FDA recently granted GMI-1271 Breakthrough Therapy designation for the treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a Phase 1 clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170905005466/en/

GlycoMimetics, Inc.Investors:Shari Annes, [e-mail]:Jamie Lacey-Moreira, [e-mail]